Effects of Topical or Intravitreal Application of Anti-Vascular Endothelial Growth Factor on Density of Intestinal Blood Vessels of Mice
Conclusions: The topical application or intravitreal injections of anti-VEGF agents do not cause a change in the VD of the intestinal vessels, which may be related to its safety.PMID:37109767 | PMC:PMC10143914 | DOI:10.3390/medicina59040809 (Source: Medicina (Kaunas))
Source: Medicina (Kaunas) - April 28, 2023 Category: Universities & Medical Training Authors: Atsushi Ichio Masahiko Sugimoto Yuhki Koike Yuji Toiyama Mineo Kondo Source Type: research
Effects of Topical or Intravitreal Application of Anti-Vascular Endothelial Growth Factor on Density of Intestinal Blood Vessels of Mice
Conclusions: The topical application or intravitreal injections of anti-VEGF agents do not cause a change in the VD of the intestinal vessels, which may be related to its safety.PMID:37109767 | PMC:PMC10143914 | DOI:10.3390/medicina59040809 (Source: Medicina (Kaunas))
Source: Medicina (Kaunas) - April 28, 2023 Category: Universities & Medical Training Authors: Atsushi Ichio Masahiko Sugimoto Yuhki Koike Yuji Toiyama Mineo Kondo Source Type: research
Refractive status and retinal morphology in children with a history of intravitreal ranibizumab for retinopathy of prematurity
Conclusion: Children with a history of type 1 ROP treated with ranibizumab did not show a myopic shift but did show abnormal retinal morphology and the poorest BCVA among all groups. We suggest that pediatric ophthalmologists should always pay attention to visual development in patients with ROP with a history of intravitreal ranibizumab.What is Known:• Anti-VEGF is efficiently and widely used in the treatment of type 1 retinopathy of prematurity (ROP), and different anti-VEGF agents are associated with different prevalence of myopia.• Patients with ROP who receive treatment such as laser therapy or cryotherapy have ab...
Source: European Journal of Pediatrics - April 25, 2023 Category: Pediatrics Source Type: research
Infographic: Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: the ANCHOR study
Eye, Published online: 24 April 2023; doi:10.1038/s41433-023-02397-zInfographic: Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: the ANCHOR study (Source: Eye)
Source: Eye - April 24, 2023 Category: Opthalmology Authors: Imran H. Yusuf Christin Henein Sobha Sivaprasad Source Type: research
Topical bromfenac as adjunctive treatment with intravitreal ranibizumab for diabetic macular edema
ConclusionTopical bromfenac 0.09% twice a day could enhance and sustain the efficacy of intravitreal ranibizumab in the treatment of diabetic macular edema without increasing the incidence of corneal side effects. (Source: International Ophthalmology)
Source: International Ophthalmology - April 21, 2023 Category: Opthalmology Source Type: research
Infographic: Ranibizumab plus panretinal photocoagulation (PRP) versus PRP alone for high-risk proliferative diabetic retinopathy (PDR): the PROTEUS study
Eye, Published online: 21 April 2023; doi:10.1038/s41433-023-02399-xInfographic: Ranibizumab plus panretinal photocoagulation (PRP) versus PRP alone for high-risk proliferative diabetic retinopathy (PDR): the PROTEUS study (Source: Eye)
Source: Eye - April 21, 2023 Category: Opthalmology Authors: Imran H. Yusuf Christin Henein Sobha Sivaprasad Source Type: research
Infographic: A randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia: the RADIANCE study
Eye, Published online: 21 April 2023; doi:10.1038/s41433-023-02392-4Infographic: A randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia: the RADIANCE study (Source: Eye)
Source: Eye - April 21, 2023 Category: Opthalmology Authors: Imran H. Yusuf Christin Henein Sobha Sivaprasad Source Type: research
Infographic: Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age-related macular degeneration: the BRAMD study
Eye, Published online: 21 April 2023; doi:10.1038/s41433-023-02398-yInfographic: Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age-related macular degeneration: the BRAMD study (Source: Eye)
Source: Eye - April 21, 2023 Category: Opthalmology Authors: Imran H. Yusuf Christin Henein Sobha Sivaprasad Source Type: research
Infographic: Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy (PDR): DRCR.net Protocol S
Eye, Published online: 21 April 2023; doi:10.1038/s41433-023-02396-0Infographic: Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy (PDR): DRCR.net Protocol S (Source: Eye)
Source: Eye - April 21, 2023 Category: Opthalmology Authors: Imran H. Yusuf Christin Henein Sobha Sivaprasad Source Type: research
Acute and subacute intraocular pressure and macular microvascular structure changes after intravitreal ranibizumab injection in eyes with branch retinal vein occlusion
To investigate early changes in the intraocular pressure (IOP) and macular microvascular structure in eyes with branch retinal vein occlusion (BRVO) treated with intravitreal Ranibizumab injection. (Source: BMC Ophthalmology)
Source: BMC Ophthalmology - April 18, 2023 Category: Opthalmology Authors: Xiaoyu Li, Qin Chen and Xiaobing Yu Tags: Research Source Type: research
Cardiovascular and Cerebrovascular Safety of Ranibizumab, Bevacizumab, and Aflibercept in Ocular Diseases: an Analysis of the FDA Adverse Event Reporting System database (FAERS)
This study aimed to evaluate and compare the cardiovascular and cerebrovascular safety in patients receiving ranibizumab, bevacizumab, and aflibercept for ocular disease. A cross-sectional study was conducted from 2017 (Q1) to 2021 (Q4) in the FAERS database. The outcomes of interest were central nervous system (CNS) vascular disorders, ischemic heart disease, hypertension, pulmonary hypertension, torsade de pointes/QT prolongation, embolic and thrombotic events, cardiac arrhythmias, cardiac failure and cardiomyopathy. Data mining was performed by a disproportional method with a compression, using reporting odds ratios (RO...
Source: The Journal of Clinical Pharmacology - April 12, 2023 Category: Drugs & Pharmacology Authors: Yanbin Zeng Xiaohui Guo Fengjiao Xiao Haixia Zhang Source Type: research
Benefits of a laser chorioretinal anastomosis plus ranibizumab vs ranibizumab alone for central retinal vein occlusion: 4-year results.
Evaluate what clinical gains can be achieved over conventional treatment with ranibizumab alone for central retinal vein occlusion (CRVO) when causal pathology is additionally successfully addressed with a laser-induced chorio-retinal anastomosis (L-CRA). (Source: American Journal of Ophthalmology)
Source: American Journal of Ophthalmology - April 6, 2023 Category: Opthalmology Authors: Ian L McAllister, Lynne A Smithies, Fred K Chen, David A Mackey, Paul G Sanfilippo Source Type: research
Comparison of post-treatment recurrence between ranibizumab injection and laser photocoagulation for type 1 retinopathy of prematurity
To compare post-treatment recurrence between ranibizumab injection and laser photocoagulation (LP) for type 1 retinopathy of prematurity (ROP), and explore the associated risk factors. (Source: BMC Ophthalmology)
Source: BMC Ophthalmology - April 4, 2023 Category: Opthalmology Authors: Jing-Ke Cao, Tao Han, Hong-Yi Tang, Sheng Zhang, Zong-Hua Wang, Zhi-Chun Feng and Qiu-Ping Li Tags: Research Source Type: research
Anti-vascular endothelial growth factor for neovascular glaucoma
CONCLUSIONS: Anti-VEGFs as an adjunct to conventional treatment could help reduce IOP in NVG in the short term (four to six weeks), but there is no evidence that this is likely in the longer term. Currently available evidence regarding the short- and long-term effectiveness and safety of anti-VEGFs in achieving control of IOP, visual acuity, and complete regression of new iris vessels in NVG is insufficient. More research is needed to investigate the effect of these medications compared with, or in addition to, conventional surgical or medical treatment in achieving these outcomes in NVG.PMID:37010901 | DOI:10.1002/1465185...
Source: Cochrane Database of Systematic Reviews - April 3, 2023 Category: General Medicine Authors: Thanitsara Rittiphairoj Gloria Roberti Manuele Michelessi Source Type: research
Anti-vascular endothelial growth factor for neovascular glaucoma
CONCLUSIONS: Anti-VEGFs as an adjunct to conventional treatment could help reduce IOP in NVG in the short term (four to six weeks), but there is no evidence that this is likely in the longer term. Currently available evidence regarding the short- and long-term effectiveness and safety of anti-VEGFs in achieving control of IOP, visual acuity, and complete regression of new iris vessels in NVG is insufficient. More research is needed to investigate the effect of these medications compared with, or in addition to, conventional surgical or medical treatment in achieving these outcomes in NVG.PMID:37010901 | PMC:PMC10069372 | D...
Source: Cochrane Database of Systematic Reviews - April 3, 2023 Category: General Medicine Authors: Thanitsara Rittiphairoj Gloria Roberti Manuele Michelessi Source Type: research
